KALA News and Press, Kala Pharmaceuticals Inc. From 03/08/22

Kala Pharmaceuticals (NASDAQ:KALA) said that UnitedHealthcare (NYSE:UNH) added dry eye disease therapy Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies effective March 2022, expanding commercial coverage to 118M people. In ...

-- Expands Commercial Coverage to 118 million lives and Medicare Coverage to 7.1 million lives -- ARLINGTON, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and ...

Intercontinental Exchange will add 138 securities to the ICE Biotechnology index and delete 26 as part of the annual reconstitution, effective prior to market open on December 20. Notable additions: Aurinia Pharmaceuticals (NASDAQ:AUPH), Anavex Life Sciences (NASDAQ:AVXL), Sesen Bio...

Short squeeze stocks are becoming a mainstay in the arsenal of trends to follow this year. Thanks to extensive breakouts from the likes of AMC Entertainment ( NYSE: AMC ), GameStop ( NYSE: GME ), and countless others, retail traders, in particular, are on the hunt for the next r...

WATERTOWN, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with Nasdaq Listing ...

The following slide deck was published by Kala Pharmaceuticals, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Kala Pharmaceuticals, Inc. 2021 Q3 - Results - Earnings Call Presentation

Kala Pharmaceuticals, Inc. (KALA) Q3 2021 Earnings Conference Call November 15, 2021 08:30 AM ET Company Participants Jill Steier – Executive Director, Investor Relations and Corporate Communications Mark Iwicki – Chairman, President and Chief Executive Officer Kim Brazzell ...

Kala Pharmaceuticals (KALA +3.4%) has acquired privately held Combangio gaining access to a candidate for persistent corneal epithelial defect ("PCED"). Terms call Combangio equityholders to receive $5M upfront, and an aggregate of 7,788,667 shares of Kala common stock with an aggregate value...

If you’re looking for the best penny stocks to buy now, you might be looking at different trends. Whether they be industry trends or something more thematic, there’s no shortage of attention-grabbing catalysts. In the stock market today, everything from electric vehicles to en...

Kala Pharmaceuticals (NASDAQ:KALA): Q3 GAAP EPS of -$0.43 in-line. Revenue of $3.1M (+39.6% Y/Y) misses by $2.06M. Press Release As of September 30, 2021, Kala had cash and cash equivalents of $124.5M, compared to $149.6M of cash, cash equivalents and short-term investments as of June 30, 202...